Theratechnologies inc.
TSX : TH

Theratechnologies inc.

December 18, 2006 16:43 ET

Theratechnologies: Notice of Conference Call & Media Advisory

Attention Business/Financial Editors and Analysts Theratechnologies reports Phase 3 clinical trial results of its lead drug candidate TH9507 in HIV-associated lipodystrophy

MONTREAL, QUEBEC--(CCNMatthews - Dec. 18, 2006) - Theratechnologies (TSX:TH) advises of an upcoming conference call and webcast to discuss the results of its Phase 3 clinical trial testing TH9507 in HIV-associated lipodystrophy. The call will be presided over by the President and CEO of Theratechnologies, Mr. Yves Rosconi. Mr. Luc Tanguay, Senior Executive Vice President and Chief Financial Officer and Dr. Koenraad Blot, M.D., Executive Director, Clinical Research, will also be participating.

The conference call will take place tomorrow, Dec. 19, 2006 at 8:00 a.m. eastern time. Prior to the call a press release will be transmitted on the CCNMatthews news wire at approximately 7:00 a.m. eastern time.

December 19, 2006 conference call and webcast

For the conference call, interested participants are asked to dial the following numbers: 416-644-3424 or 1-800-731-6941 (toll free). Please call five (5) minutes prior to the conference in order to ensure your participation. You can access the webcast at the following links: www.investorcalendar.com and http://www.theratech.com/.

A replay of the conference call will be available as of Dec.19 , 2006 at 10:00 a.m. until Dec. 26, 2006 at 11:59 p.m. at the following number: 416-640-1917, pass code 21214033# or 1-877-289-8525, code 21214033#. The webcast will be posted for 90 days at the following links: www.investorcalendar.com and www.theratech.com.

About Theratechnologies

Theratechnologies (TSX:TH) is a Canadian biopharmaceutical company that discovers or acquires novel therapeutic products for development and commercialization. These products target unmet medical needs in commercially attractive specialty markets. The most advanced program is TH9507 in Phase 3 clinical development in HIV-associated lipodystrophy. The Company also has other promising projects at various stages of development.

Contact Information